Ironwood Pharmaceuticals, Inc. (IRWD)
- Previous Close
8.10 - Open
8.24 - Bid 7.97 x 1200
- Ask 8.04 x 600
- Day's Range
7.96 - 8.05 - 52 Week Range
7.53 - 15.70 - Volume
135,388 - Avg. Volume
4,561,704 - Market Cap (intraday)
1.253B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-6.45 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
www.ironwoodpharma.com267
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: IRWD
Performance Overview: IRWD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IRWD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IRWD
Valuation Measures
Market Cap
1.27B
Enterprise Value
1.89B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.84
Price/Book (mrq)
--
Enterprise Value/Revenue
4.27
Enterprise Value/EBITDA
-2.04
Financial Highlights
Profitability and Income Statement
Profit Margin
-226.37%
Return on Assets (ttm)
13.39%
Return on Equity (ttm)
-674.04%
Revenue (ttm)
442.74M
Net Income Avi to Common (ttm)
-1B
Diluted EPS (ttm)
-6.45
Balance Sheet and Cash Flow
Total Cash (mrq)
92.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
186.79M
Research Analysis: IRWD
Company Insights: IRWD
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: IRWD
IRWD: Raising target price to $9.00
IRONWOOD PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetIRWD: What does Argus have to say about IRWD?
IRONWOOD PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetIRWD: Lowering target price to $8.00
IRONWOOD PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetIRWD: What does Argus have to say about IRWD?
IRONWOOD PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target